Literature DB >> 25043623

Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia-reperfusion injury.

Hideki Motoyama1, Fengshi Chen1, Kyoko Hijiya1, Takeshi Kondo1, Akihiro Ohsumi1, Tetsu Yamada1, Masaaki Sato1, Akihiro Aoyama1, Toru Bando1, Hiroshi Date2.   

Abstract

BACKGROUND: Donor lung thrombus is considered a significant etiology for primary graft dysfunction (PGD). We hypothesized that thrombolysis in ex vivo lung perfusion (EVLP) before lung transplantation could alleviate ischemia-reperfusion injury (IRI), resulting in a decreased incidence of PGD.
METHODS: Rats were divided into control (n = 5), non-plasmin (n = 7) and plasmin (n = 7) groups. In the non-plasmin and plasmin groups, cardiac arrest was induced by withdrawal of ventilation without heparinization. After 120 minutes of warm ischemia, the lungs were ventilated and flushed. Hearts and both lungs were excised en bloc. The lungs were perfused and ventilated in the EVLP for 30 minutes, and plasmin or placebo was administered on EVLP initiation. The lungs were then stored at 4°C for 90 minutes and finally perfused with rat blood for 80 minutes. We assessed physiologic and histologic findings during reperfusion and the correlation between physiologic data during EVLP and after reperfusion.
RESULTS: Physiologic results were better in the plasmin group than in the non-plasmin group. The plasmin group lungs had fewer signs of histologic injury. Caspase-3 and -7 activity in the plasmin group was lower in the non-plasmin group. Pulmonary vascular resistance (PVR) during EVLP correlated with that at the end of reperfusion.
CONCLUSIONS: Plasmin administration during EVLP protected the donor lungs after reperfusion. We also found that several physiologic values in EVLP may be predictive markers of lung function after reperfusion.
Copyright © 2014 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ex vivo lung perfusion; fibrinolytic treatment; lung transplantation; marginal donor; plasmin

Mesh:

Substances:

Year:  2014        PMID: 25043623     DOI: 10.1016/j.healun.2014.06.004

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Reduced-flow ex vivo lung perfusion to rehabilitate lungs donated after circulatory death.

Authors:  Jared P Beller; Matthew R Byler; Dustin T Money; William Z Chancellor; Aimee Zhang; Yunge Zhao; Mark H Stoler; Adishesh K Narahari; Alexander Shannon; J Hunter Mehaffey; Curtis G Tribble; Victor E Laubach; Irving L Kron; Mark E Roeser
Journal:  J Heart Lung Transplant       Date:  2019-09-18       Impact factor: 10.247

Review 2.  Primary graft dysfunction: pathophysiology to guide new preventive therapies.

Authors:  Ciara M Shaver; Lorraine B Ware
Journal:  Expert Rev Respir Med       Date:  2017-01-20       Impact factor: 3.772

Review 3.  Ex-vivo lung perfusion therapies: do they add value to organ donation?

Authors:  Amit Lyengar; Alexis Schiazza; Edward Cantu
Journal:  Curr Opin Organ Transplant       Date:  2022-06-01       Impact factor: 2.269

4.  Experimental Models of Ischemic Lung Damage for the Study of Therapeutic Reconditioning During Ex Vivo Lung Perfusion.

Authors:  Roumen Parapanov; Xingyu Wang; Yabo Wang; Anne Debonneville; Jérôme Lugrin; Lucas Liaudet; Thorsten Krueger
Journal:  Transplant Direct       Date:  2022-06-10

5.  Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury.

Authors:  Cong Liu; Yana Ma; Zhenlei Su; Runzhen Zhao; Xiaoli Zhao; Hong-Guang Nie; Ping Xu; Lili Zhu; Mo Zhang; Xiumin Li; Xiaoju Zhang; Michael A Matthay; Hong-Long Ji
Journal:  Front Immunol       Date:  2018-08-20       Impact factor: 7.561

6.  Donor leukocyte trafficking during human ex vivo lung perfusion.

Authors:  Andy Chao Hsuan Lee; Arianna Edobor; Thirushan Wigakumar; Maria Lysandrou; Laura K Johnston; Phillip McMullen; Vikranth Mirle; Ashley Diaz; Ryan Piech; Rebecca Rose; Martin Jendrisak; Diego di Sabato; Kumaran Shanmugarajah; John Fung; Jessica Donington; Maria Lucia Madariaga
Journal:  Clin Transplant       Date:  2022-04-18       Impact factor: 3.456

Review 7.  Ischemia-Reperfusion Injury in Lung Transplantation.

Authors:  Toyofumi Fengshi Chen-Yoshikawa
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

8.  Donor Leukocyte Trafficking and Damage-associated Molecular Pattern Expression During Ex Vivo Lung Perfusion.

Authors:  Robert P Davis; John Yerxa; Qimeng Gao; Jared Gloria; Uwe Scheuermann; Mingqing Song; Min Zhang; William Parker; Jaewoo Lee; Matthew G Hartwig; Andrew S Barbas
Journal:  Transplant Direct       Date:  2020-02-10

9.  Subnormothermic ex vivo lung perfusion attenuates ischemia reperfusion injury from donation after circulatory death donors.

Authors:  Stephan Arni; Tatsuo Maeyashiki; Isabelle Opitz; Ilhan Inci
Journal:  PLoS One       Date:  2021-08-02       Impact factor: 3.240

Review 10.  The potential of ex vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury.

Authors:  Jasper Iske; Christopher A Hinze; Jawad Salman; Axel Haverich; Stefan G Tullius; Fabio Ius
Journal:  Am J Transplant       Date:  2021-08-24       Impact factor: 8.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.